Recent ACOR News
- Webcast/Conference Call Scheduled for April 1, 2024 • Business Wire • 03/25/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 01:33:43 PM
- Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025 • Business Wire • 01/11/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 09:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:16:04 PM
- Acorda Therapeutics Reports Third Quarter 2023 Financial Results • Business Wire • 11/13/2023 09:01:00 PM
- Webcast/Conference Call Scheduled for November 13, 2023 • Business Wire • 11/06/2023 09:01:00 PM
- Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA® • Business Wire • 11/06/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:12:23 PM
- Acorda Therapeutics Reports Second Quarter 2023 Financial Results • Business Wire • 08/08/2023 08:01:00 PM
- Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™” • Business Wire • 08/02/2023 12:00:00 PM
- Webcast/Conference Call Scheduled for August 8, 2023 • Business Wire • 08/01/2023 12:00:00 PM
- Tom Burns Elected to the Acorda Therapeutics Board of Directors • Business Wire • 06/28/2023 09:08:00 PM
- Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement • Business Wire • 06/26/2023 12:23:00 PM
- Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement • Business Wire • 06/26/2023 12:00:00 PM
- Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split • Business Wire • 06/02/2023 08:01:00 PM
- Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split • Business Wire • 05/31/2023 08:01:00 PM
- Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A • Business Wire • 05/30/2023 12:00:00 PM
- Acorda Therapeutics Reports First Quarter 2023 Financial Results • Business Wire • 05/11/2023 08:01:00 PM
- Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash • Business Wire • 05/10/2023 11:00:00 AM
- Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China • Business Wire • 05/08/2023 11:00:00 AM
- Webcast/Conference Call Scheduled for May 11, 2023 • Business Wire • 05/04/2023 01:41:00 PM
- Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting • Business Wire • 04/24/2023 12:00:00 PM
- Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month • Business Wire • 04/03/2023 12:00:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM